PL1763356T3 - Kompozycja zawierająca antysensowny oligonukleotyd surwiwiny i gemcytabinę do leczenia raka - Google Patents

Kompozycja zawierająca antysensowny oligonukleotyd surwiwiny i gemcytabinę do leczenia raka

Info

Publication number
PL1763356T3
PL1763356T3 PL05738307T PL05738307T PL1763356T3 PL 1763356 T3 PL1763356 T3 PL 1763356T3 PL 05738307 T PL05738307 T PL 05738307T PL 05738307 T PL05738307 T PL 05738307T PL 1763356 T3 PL1763356 T3 PL 1763356T3
Authority
PL
Poland
Prior art keywords
cancer
antisense oligonucleotide
gemcitabine
treatment
composition
Prior art date
Application number
PL05738307T
Other languages
English (en)
Inventor
Bharvin Kumar Patel
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PL1763356T3 publication Critical patent/PL1763356T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL05738307T 2004-04-22 2005-04-15 Kompozycja zawierająca antysensowny oligonukleotyd surwiwiny i gemcytabinę do leczenia raka PL1763356T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56454004P 2004-04-22 2004-04-22
PCT/US2005/012968 WO2005107771A2 (en) 2004-04-22 2005-04-15 Composition comprising a survivin oligonucleotide and gemcitabine for the treatment of cancer
EP05738307A EP1763356B1 (en) 2004-04-22 2005-04-15 Composition comprising a survivin antisense oligonucleotide and gemcitabine for the treatment of cancer

Publications (1)

Publication Number Publication Date
PL1763356T3 true PL1763356T3 (pl) 2008-12-31

Family

ID=35094133

Family Applications (2)

Application Number Title Priority Date Filing Date
PL07119706T PL1913947T3 (pl) 2004-04-22 2005-04-15 Terapia skojarzona do leczenia raka
PL05738307T PL1763356T3 (pl) 2004-04-22 2005-04-15 Kompozycja zawierająca antysensowny oligonukleotyd surwiwiny i gemcytabinę do leczenia raka

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL07119706T PL1913947T3 (pl) 2004-04-22 2005-04-15 Terapia skojarzona do leczenia raka

Country Status (17)

Country Link
US (3) US20070244065A1 (pl)
EP (3) EP1763356B1 (pl)
JP (1) JP2007533742A (pl)
CN (2) CN101683355A (pl)
AT (2) ATE401088T1 (pl)
AU (1) AU2005240020B2 (pl)
BR (1) BRPI0509927A (pl)
CA (1) CA2562750A1 (pl)
CY (2) CY1110440T1 (pl)
DE (1) DE602005008241D1 (pl)
DK (2) DK1913947T3 (pl)
ES (2) ES2308488T3 (pl)
MX (1) MXPA06012132A (pl)
PL (2) PL1913947T3 (pl)
PT (2) PT1913947E (pl)
SI (2) SI1913947T1 (pl)
WO (1) WO2005107771A2 (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3266453A1 (en) 2008-07-03 2018-01-10 Mayo Foundation for Medical Education and Research Treating cancer
FR2955112B1 (fr) 2010-01-14 2012-01-20 Isp Investments Inc Nouveaux peptides anti-age modulateurs de la survivine et compositions les comprenant
WO2012058462A2 (en) * 2010-10-29 2012-05-03 Isis Pharmaceuticals, Inc. Combination therapy for the treatment of cancer
HUE048876T2 (hu) 2011-05-09 2020-08-28 Mayo Found Medical Education & Res Rákos megbetegedések kezelése
US10413606B2 (en) 2012-10-01 2019-09-17 Mayo Foundation For Medical Education And Research Methods for treating cancer with nanoparticle complexes of albumin-bound paclitaxel and anti-VEGF antibodies
EP3154586B1 (en) 2014-06-13 2020-05-27 Mayo Foundation for Medical Education and Research Treating lymphomas
US10213513B2 (en) 2014-06-16 2019-02-26 Mayo Foundation For Medical Education And Research Treating myelomas
CN107073132B (zh) 2014-10-06 2021-08-27 梅约医学教育与研究基金会 载体-抗体组合物及其制备和使用方法
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體-抗體組合物及其製造及使用方法
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
WO2017120501A1 (en) 2016-01-07 2017-07-13 Mayo Foundation For Medical Education And Research Methods of treating cancer with interferon
US11351254B2 (en) 2016-02-12 2022-06-07 Mayo Foundation For Medical Education And Research Hematologic cancer treatments
EP3432928A4 (en) 2016-03-21 2019-11-20 Mayo Foundation for Medical Education and Research PROCESS FOR IMPROVING THE THERAPEUTIC INDEX FOR CHEMOTHERAPEUTIC
WO2017165440A1 (en) 2016-03-21 2017-09-28 Mayo Foundation For Medical Education And Research Methods for reducing toxicity of a chemotherapeutic drug
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
CN109890419A (zh) 2016-09-01 2019-06-14 梅约医学教育与研究基金会 用于治疗癌症的载体-pd-l1结合剂组合物
CN109843336A (zh) 2016-09-01 2019-06-04 梅约医学教育与研究基金会 用于靶向t细胞癌症的方法和组合物
CN109843924A (zh) 2016-09-06 2019-06-04 梅约医学教育与研究基金会 治疗表达pd-l1的癌症的方法
US11590098B2 (en) 2016-09-06 2023-02-28 Mayo Foundation For Medical Education And Research Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
AU2017324947A1 (en) 2016-09-06 2019-03-28 Mayo Foundation For Medical Education And Research Paclitaxel-albumin-binding agent compositions and methods for using and making the same
AU2020356931A1 (en) * 2019-10-02 2022-05-26 Sirnaomics, Inc. Oligonucleotides with nucleoside analogs

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3587500T2 (de) * 1984-12-04 1993-12-16 Lilly Co Eli Tumorbehandlung bei Säugetieren.
US6077709A (en) * 1998-09-29 2000-06-20 Isis Pharmaceuticals Inc. Antisense modulation of Survivin expression
US6838283B2 (en) * 1998-09-29 2005-01-04 Isis Pharmaceuticals Inc. Antisense modulation of survivin expression
US6335194B1 (en) * 1998-09-29 2002-01-01 Isis Pharmaceuticals, Inc. Antisense modulation of survivin expression
CA2515623A1 (en) * 2003-02-10 2004-08-19 Santaris Pharma A/S Oligomeric compounds for the modulation of survivin expression

Also Published As

Publication number Publication date
EP1763356B1 (en) 2008-07-16
US20090247611A1 (en) 2009-10-01
CY1110440T1 (el) 2015-04-29
BRPI0509927A (pt) 2007-09-25
ES2308488T3 (es) 2008-12-01
AU2005240020B2 (en) 2011-02-10
PT1763356E (pt) 2008-09-05
CY1112397T1 (el) 2015-12-09
ES2376484T3 (es) 2012-03-14
DK1913947T3 (da) 2012-02-06
SI1763356T1 (sl) 2008-12-31
PL1913947T3 (pl) 2012-05-31
ATE401088T1 (de) 2008-08-15
EP1913947B1 (en) 2011-12-28
JP2007533742A (ja) 2007-11-22
WO2005107771A2 (en) 2005-11-17
US20120022140A1 (en) 2012-01-26
AU2005240020A1 (en) 2005-11-17
CA2562750A1 (en) 2005-11-17
CN1950094A (zh) 2007-04-18
EP1763356A2 (en) 2007-03-21
DK1763356T3 (da) 2008-10-13
PT1913947E (pt) 2012-01-19
MXPA06012132A (es) 2007-01-17
EP2145626A1 (en) 2010-01-20
WO2005107771A3 (en) 2006-06-08
US20070244065A1 (en) 2007-10-18
DE602005008241D1 (de) 2008-08-28
CN101683355A (zh) 2010-03-31
ATE538800T1 (de) 2012-01-15
EP1913947A1 (en) 2008-04-23
SI1913947T1 (sl) 2012-02-29

Similar Documents

Publication Publication Date Title
SI1763356T1 (sl) Zmes, ki vsebuje survivin s protismernimi oligonukleotidi in gemcitabin za zdravljenje raka
WO2008137867A3 (en) Compositions comprising mir34 therapeutic agents for treating cancer
WO2004093831A3 (en) Cytokine-expressing cellular vaccine combinations
PH12012502380B1 (en) Methods of treatment of pancreatic cancer
MX2009006466A (es) Metodos de tratamiento de cancer con inhibidores del receptor del factor 1 de crecimiento similar a la insulina.
WO2005051429A3 (en) Targeted conjugates with a modified saccharide linker
IN2012DN02018A (pl)
SG161259A1 (en) Method for treatment of constipation-predominant irritable bowel syndrome
MX2007009960A (es) Combinaciones y metodos de administracion de agentes terapeuticos y terapia de combinacion.
WO2004004661A3 (en) Boroproline compound combination therapy
MX2010006519A (es) Metodo para tratar una fractura de hueso con anticuerpos anti-esclerostina.
MXPA05012421A (es) Tratamiento sinergistico de cancer usando inmunomeros junto con agentes quimioterapeuticos.
MX2007002398A (es) Nuevas composiciones farmaceuticas para el tratamiento de cancer.
MX352412B (es) Tratamiento de enfermedades relacionadas con eritropoyetina (epo) mediante inhibicion del transcrito antisentido natural a eritropoyetina.
UA90467C2 (ru) Применение пептидных соединений для лечения боли при болезненой диабетической невропатии
MX2009003532A (es) Tratamiento de hiperbilirrubinemia infantil utilizando bajas dosis de estansoporfina.
WO2006128125A3 (en) Methods of and compositions for stimulation of glucose uptake into muscle cells and treatment of diseases
WO2007134203A3 (en) Anticancer treatments with a combination of docetaxel and ecteinascidin
MX2007004955A (es) Metodo de tratar cancer con formulaciones de compeusto de platino a base de lipido administradas intraperitonealmente.
WO2007130501A3 (en) Combination therapy for treatment of cancer
AR062248A1 (es) Composiciones y metodos para tratar artritis reumatoidea
UA93516C2 (ru) Способы лечения b-клеточных злокачественных образований c помощью слитой молекулы taci-ig
MXPA05013975A (es) Tratamiento de enfermedades asociadas con amiloide y epileptogenesis.
MXPA05011568A (es) Uso de irinotecan para el tratamiento de cancer recurrente de mama.
ATE537838T1 (de) Kombinationstherapie mit kloretazin(tm)